Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | November 08, 2013

The Hottest Topics and Technologies in Interventional Cardiology at TCT 2013

By Dave Fornell, DAIC editor

The Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2013 meeting brought many new insights about the latest cardiovascular technologies and treatment techniques. Among the hottest topics were transcatheter heart valve repairs, renal denervation to treat drug resistant hypertension, left atrial appendage (LAA) occluders to prevent stroke and eliminate warfarin therapy in atrial fibrillation patients, bifurcation stenting trials and techniques, new insights on anti-clotting agents, increasing use of ultrasound and intravascular imaging, new technologies for FFR lesion assessments, and the latest stent trial data.

I offer my editor’s choice for the most innovative new technologies presented in sessions and on the show floor in a video format.

For a video of the top meeting highlights, Herb Aronow, M.D., offers his views on some of the most interesting topics discussed in sessions.

The most exciting interventional device to enter the U.S. market a couple days prior to TCT was Abbott's MitraClip. We conducted a video interview with the lead author of the MitraClip FDA pivotal trial at TCT.

Here is a summary of some of the top news from TCT. You can click on any item to read the full story.

CoreValve shows outcomes as good or better that Sapien

CT-FFR shown to be comparable to invasive FFR

Dedicated Tryton bifurcation stent did not meet primary endpoint

Provisional vs. two-stent bifurcation therapy has similar outcomes

Data promising for first FDA drug-eluting balloon trial

Simplified, non-adenosine iFR compares favorably with standard FFR

Hypothermia for STEMI safe, but did not reduce infarct size

Thrombectomy does not improve outcomes in NSTEMI PCI

MitraClip trial data leads to FDA approvalVideo interview with lead author of study

Bioresorbable polymer coated stent equal to traditional DES

Boston Scientific’s Lotus TAVR valve meets primary endpoints in REPRISE II

Pre-hospital bivalirudin for STEMI improves outcomes

• Data from two trials (ARCTIC-INTERRUPTION and OPTIMIZE) shows short-duration DAPT is feasible

Genetic profiling for CYP2C19 antiplatelet agents improves outcomes

Transradial access lowers bleeding risks in women

In addition to these news items, listed below are more top trial summaries and new product releases.

Related Content

Abbott Amplatzer Amulet LAA Occluder Offers Superior Closure Compared to Watchman
News | Left Atrial Appendage (LAA) Occluders | August 31, 2021
August 31, 2021 — Late-breaking data from a head-to-head clinical trial of the Amulet Left Atrial Appendage (LAA) Occ
The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021. #LAA

The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021.

News | Left Atrial Appendage (LAA) Occluders | August 16, 2021
August 16, 2021 — The U.S.
The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry. #ACC21 #ACC2021 #LAA #Watchman

The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry.

Feature | Left Atrial Appendage (LAA) Occluders | May 16, 2021
May 15, 2021 - Transcatheter...
In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart.  #ACC21 #ACC2021

In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart. 

News | Left Atrial Appendage (LAA) Occluders | May 15, 2021
May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or...
Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage closure (LAAC) CLAAS device performed in the U.S. and Prague were presented at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual meeting. Two two abstracts were presented by William Gray, M.D., from Lankenau Heart Institute, Wynnewood, Penn., and Vivek Reddy, M.D., from Mount Sinai Hospital in New York. #TCT2020 #TCTconnect
News | Left Atrial Appendage (LAA) Occluders | October 16, 2020
October 16, 2020 — Positive clinical data from first-in-human studies of the Conformal Medical...
Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization.

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization. Read more on this FDA approval.

News | Left Atrial Appendage (LAA) Occluders | August 21, 2020
August 21, 2020 — According to a report published by Research Dive, the rising number of patients suffering from...
The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy. #LAA #LAAC

The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy.

News | Left Atrial Appendage (LAA) Occluders | August 06, 2020
August 6, 2020 – Conformal Medical Inc.